Pneumonia, Thrombocytopenia
Conditions
Brief summary
The incidence of thrombocytopenia in ICU patients with severe illness ranged from 8.3% to 67.6%, and ranged from 14% to 44% during ICU treatment.Severe patients with thrombocytopenia also have significantly increased bleeding events and blood transfusions, and even a significantly increased risk of death.This study examines whether elevated platelets benefit patients with pneumonia
Interventions
The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
DRUGnormal saline
Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
Sponsors
The Third Affiliated Hospital of Southern Medical University
The Second People's Hospital of GuangDong Province
Shenzhen Hospital of Southern Medical University
Nanfang Hospital, Southern Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of pneumonia (community acquired pneumonia, hospital acquired pneumonia or ventilator associated pneumonia); * Voluntarily signed informed consent; * ≥18 years old; * Platelet count ≤75×109/L
Exclusion criteria
* A history of hematopoietic stem cell transplantation or solid organ transplantation such as liver, kidney or lung; * Hematological malignancy; * Immune thrombocytopenia, such as SLE, ITP, TTP, etc. * The length of stay in ICU is less than 24h; * Pregnant or lactation patients;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time to recovery to a normal platelet level | 14 days | The clinical recovery time of platelets was defined as the time it takes to reach clinical recovery. |
Contacts
Primary ContactZhenhua Zeng
Outcome results
None listed